Kymera Therapeutics to report Q3 2026 financial results on October 29, 2026

Kymera Therapeutics, a clinical-stage biopharmaceutical company specializing in oral small molecule degrader medicines for immunological diseases, will announce its third quarter 2026 financial results on October 29, 2026. The company will host a video conference and webcast at 8:30 a.m. ET on the same day, providing investors and the public an opportunity to learn about its financial performance and ongoing developments. Kymera is known for pioneering targeted protein degradation therapies and advancing treatments for diseases that are difficult to address with conventional medicines. This earnings report will offer insights into the company's progress and future plans in the biotech sector.

As Kymera Therapeutics prepares to release its third quarter 2026 financial results on October 29, 2026, investors can note that its stock is currently priced at USD 110.88 on Pluang, down 1.56% over the past day as of October 23, 2026 03:11 WIB. The company holds a market capitalization of $9.37 billion, reflecting its significant presence in the health sector. Kymera's shares have traded between $55.80 and $127.31 over the past year, with a typical hold time of 8 days on Pluang.